Why the study?
Does etoricoxib reduce gastrointestinal toxicity compared to non-selective NSAIDs and placebo in subjects and patients with osteoarthritis or rheumatoid arthritis?
Population
804 subjects across two studies: 62 subjects and 742 osteoarthritis or rheumatoid arthritis patients
Comparison
Etoricoxib 120 mg once daily vs Ibuprofen 800 mg t.d.s., naproxen 500 mg b.d…
Design
RCT, randomized, double-blind
Follow-up
28 days (Study 1) and 12 weeks (Study 2)
Authors
Loading...
Supports etoricoxib preference over nonselective NSAIDs to reduce GI toxicity in arthritis; confirms COX-2 selectivity benefits on blood-loss and ulcer endpoints.
Does etoricoxib reduce gastrointestinal toxicity compared to non-selective NSAIDs and placebo in subjects and patients with osteoarthritis or rheumatoid arthritis?
Etoricoxib demonstrates a superior gastrointestinal safety profile compared to non-selective NSAIDs like ibuprofen and naproxen.
Hunt et al. (2003) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: